PHII TRIAPINE W/ GEMCITABINE ADENOCARCINOMA OF BILIARY DUCTS AND GALL BLADDER

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary objectives are to: determine the objective response rates for the combination of triapine and gemcitabine in patients with primary tumors of the biliary ducts and gall bladder; assess the toxicities and recovery from toxicities for patients with biliary duct and gall baldder tumors treated with the combination of triapine and gemcitabine; and determine the survival and progression free survival of patients with biliary and gall bladder tumors treated with combination of triapine and gemcitabine.